Cormorant Asset Management’s Tango Therapeutics TNGX Stock Holding History

Cormorant Asset Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.6M	Sell	1,300,000 -125,000	-9%	-$3.09M	2.08%	17
2026 Q1	$29.8M	Buy	+1,425,000	New	+$19.8M	1.5%	20
2023 Q2	–	Sell	-4,116,949	Closed	-$16.3M	–	75
2023 Q1	$16.3M	Hold	4,116,949	–	–	1.07%	26
2022 Q4	$29.8M	Hold	4,116,949	–	–	2%	15
2022 Q3	$14.9M	Sell	4,116,949 -390,894	-9%	-$1.67M	1.04%	33
2022 Q2	$20.4M	Sell	4,507,843 -391,342	-8%	-$2.37M	1.54%	23
2022 Q1	$37.1M	Hold	4,899,185	–	–	2.85%	12
2021 Q4	$53.1M	Buy	4,899,185 +1,000,000	+26%	+$12M	3.16%	9
2021 Q3	$48.8M	Buy	3,899,185 +3,099,185	+387%	+$37.1M	1.98%	15
2021 Q2	$9.1M	Hold	800,000	–	–	0.31%	66
2021 Q1	$8.9M	Hold	800,000	–	–	0.2%	77
2020 Q4	$9.15M	Hold	800,000	–	–	0.22%	69
2020 Q3	$8.37M	Buy	+800,000	New	+$8.17M	0.32%	64

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Cormorant Asset Management's TNGX Position: Q2 2026 in Review

Cormorant Asset Management reduced its Tango Therapeutics (TNGX) stake by 8.8% in Q2 2026, selling an estimated $3.09M and leaving 1,300,000 shares worth $40.6M. The position accounts for 2.08% of the portfolio, ranked #17.

Cormorant Asset Management first reported a position in TNGX in Q3 2020 and has held it in 13 quarters since. The position peaked at $53.1M in Q4 2021. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Cormorant Asset Management held 1,300,000 shares of Tango Therapeutics worth $40.6M as of Q2 2026.
Cormorant Asset Management sold 125,000 Tango Therapeutics shares in Q2 2026, an estimated $3.09M.
Tango Therapeutics made up 2.08% of Cormorant Asset Management's portfolio in Q2 2026, its #17 holding.
Cormorant Asset Management first reported a position in Tango Therapeutics in Q3 2020 and has held it in 13 quarters since.
Cormorant Asset Management's Tango Therapeutics position peaked at $53.1M in Q4 2021.
248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.